ETFsXtrackers MSCI Global SDGs UCITS ETF 1C
Xtrackers
Xtrackers MSCI Global SDGs UCITS ETF 1C
XDGI LSEAccumulatingIreland
Last close · EUR
30.76EUR
-0.55% · -€0.17
Published closes: 29 Oct 2026 - 30 Oct 2026
30 Oct 2026, close
XDGIBase
- Fund charges
- Not publishedFee basis unverified
- Fund size
- Not published
- Return 1Y
- +5.7%
- Sharpe 3Y
- 0.22
- Volatility 1Y
- 10.1%annualised
- Holdings
- 209Fund holdings
Performance
Compare
- XDGI+5.7%
- Price, EUR
Returns
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|
| XDGI | -0.8% | -0.5% | +0.8% | +8.4% | +5.7% | +21.0% | - |
| MSCI World | +0.4% | +4.9% | +10.8% | +16.3% | +15.9% | +75.5% | +71.2% |
| Gap to MSCI World | -1.3% | -5.3% | -10.0% | -7.9% | -10.2% | -54.5% | - |
Risk and return
Sharpe ratio · 3Y
0.22
Below MSCI World · 1.24- Return p.a.
- +4.9%
- Volatility
- 12.9%
- Max loss
- -20.7%Apr 2025
Sharpe vs indices
MSCI World
1.24
S&P 500
1.21
STOXX Europe 600
1.04
MSCI Emerging Markets IMI
0.93
CAC 40
0.37
XDGI
0.22
Method
Weekly EUR returns from adjusted closes. Sharpe is the annualised excess return over the euro overnight rate (Xtrackers II EUR Overnight Rate Swap UCITS ETF 1C) divided by its volatility. Max loss uses daily closes.
Top holdings
- Top 10
- 32.8%
- Holdings
- 209
- As of
- 1GILEAD SCIENCESUS37555810365.19%
- 2NVIDIAUS67066G10404.41%
- 3MARVELL TECHNOLOGYUS57387410414.08%
- 4VERTEX PHARMACEUTICALSUS92532F10033.73%
- 5BRISTOL MYERS SQUIBBUS11012210833.17%
- 6FIRST SOLARUS33643310703.01%
- 7VESTAS WIND SYSTEMSDK00615399212.67%
- 8KIMBERLY CLARKUS49436810352.41%
- 9REGENERON PHARMACEUTICALSUS75886F10752.19%
- 10MODERNAUS60770K10791.90%
Countries
United States51.6%
Other12.4%
JP
CN
DK
FR
TW
GB
DE
CA
NL
- Largest
- 51.6%United States
- Top 3
- 66.5%
- Effective number
- 3.51 / HHI
Market cap
Weight vs holdings
32.8%of the fund sits in the top 10 holdings
32.8%32.7%34.1%
WeightHoldings
40150
- Holdings 1-10
- Holdings 11-50
- Holdings 51-200
- Holdings 201+
Size split
Not published
Compare ETFs in Copio.
Factual research, without a suitability score or investment recommendation. Past relationships can change.
